
Apollo Endosurgery APEN
Annual report 2022
added 03-30-2023
Apollo Endosurgery Book Value 2011-2026 | APEN
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Apollo Endosurgery
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.6 M | 61.2 M | 6.75 M | 2.12 M | 28.8 M | 49.9 M | 42.4 M | 10.5 M | 15.8 M | 9.97 M | 14.9 M | 629 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 61.2 M | 629 K | 23 M |
Quarterly Book Value Apollo Endosurgery
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 42.3 M | - | 55 M | 61.2 M | -92 K | 2.71 M | 2.69 M | 6.75 M | 6.75 M | 6.75 M | 6.75 M | 2.12 M | 2.12 M | 2.12 M | 2.12 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 49.9 M | 49.9 M | 49.9 M | 49.9 M | 42.4 M | 42.4 M | 42.4 M | 42.4 M | 11.2 M | 10.5 M | 10.5 M | 10.5 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 9.97 M | 9.97 M | 9.97 M | 9.97 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 629 K | 629 K | 629 K | 629 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 61.2 M | -92 K | 19.4 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
9.52 M | $ 1.35 | - | $ 21.8 M | ||
|
Orthofix Medical
OFIX
|
450 M | $ 11.72 | -1.26 % | $ 464 M | ||
|
LENSAR
LNSR
|
18.6 M | $ 5.56 | -8.4 % | $ 64 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
AxoGen
AXGN
|
129 M | $ 32.61 | 2.71 % | $ 1.5 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 36.56 | -0.19 % | $ 1.13 B | ||
|
Penumbra
PEN
|
1.43 B | $ 334.17 | -0.41 % | $ 13 B | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
43.2 M | $ 24.7 | 0.86 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Insulet Corporation
PODD
|
1.52 B | $ 225.5 | -0.7 % | $ 15.9 B | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
11.1 M | $ 0.7 | 3.3 % | $ 38.1 M | ||
|
Aethlon Medical
AEMD
|
5.12 M | $ 2.16 | -6.09 % | $ 3.37 M | ||
|
Profound Medical Corp.
PROF
|
31.2 M | $ 5.15 | -4.63 % | $ 180 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Quanterix Corporation
QTRX
|
296 M | $ 3.82 | -3.05 % | $ 163 M | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 11.48 | 10.7 % | $ 1.55 B | ||
|
Myomo
MYO
|
11.4 M | $ 0.7 | -1.83 % | $ 29.3 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
189 M | $ 2.4 | -1.64 % | $ 141 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 3.91 | 4.83 % | $ 146 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 15.91 | -3.4 % | $ 373 M | ||
|
Outset Medical
OM
|
127 M | $ 3.53 | -2.35 % | $ 53.7 K | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 52.07 | -0.17 % | $ 1.53 B | ||
|
Sintx Technologies
SINT
|
2.93 M | $ 2.57 | 0.78 % | $ 7.13 M | ||
|
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.31 | -5.76 % | $ 53.3 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Sensus Healthcare
SRTS
|
48.1 M | $ 3.96 | -3.65 % | $ 64.7 M | ||
|
InspireMD
NSPR
|
55.2 M | $ 1.79 | 3.47 % | $ 115 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M |